The ErbB2-targeting antibody, trastuzumab (Herceptin), has remarkable therapeutic efficacy in certain patients with ErbB2overexpressing tumors. The overall trastuzumab response rate, however, is limited and what determines trastuzumab response is poorly understood. Here we report that PTEN activation contributes to trastuzumab's antitumor activity.
Introduction
, the induction of G 1 arrest and the cyclin-dependent kinase inhibitor p27 kip1 (Sliwkowski et al., 1999) , and the inhibition Overexpression of ErbB2, a 185 kDa membrane receptor tyroof ErbB2 ectodomain cleavage (Molina et al., 2001) . Despite sine kinase, is found in 20%-30% of human breast cancers and these and other reported functions that result from ErbB2 downmany other cancer types (Slamon et al., 1987; Yu and Hung, regulation (Petit et al., 1997) , the mechanism of trastuzumab's 2000). ErbB2 overexpression leads to a very aggressive cancer antitumor activity remains a fundamental question to be clearly phenotype and poor patient survival (Slamon et al., 1987; Yu addressed (Baselga and Albanell, 2001) . and . Numerous efforts have been directed at devel-As the only FDA-approved therapeutic antibody for metaoping ErbB2-targeting cancer therapies (Bange et al., 2001) . static breast cancer, trastuzumab has demonstrated durable One successful example is the recombinant humanized antiresponses as a single agent and striking therapeutic efficacy in combination with other chemotherapeutics (Cobleigh et al., ErbB2 monoclonal antibody trastuzumab (Herceptin) that specifically binds to the extracellular domain of ErbB2 (Cho et al., 1999; Esteva et al., 2002; Seidman et al., 2001; Slamon et al., 2001) . However, less than 35% of patients with ErbB2-2003; Shepard et al., 1991) . The currently known mechanisms underlying trastuzumab's antitumor activity include the down-overexpressing metastatic breast cancer respond to trastuzumab as a single agent, whereas ‫%5ف‬ of patients suffer from regulation of p185 ErbB2 and the subsequent inhibition of its downstream PI3K-Akt signaling pathway (Hudziak et al., 1989; Yakes severe side effects (e.g., cardiac dysfunction) and 40% of pa-tients experience other adverse effects from trastuzumab treat-( Figure 1B) . Contrarily, the p85 subunit of PI3K had a transiently increased association with the ErbB2 complex ( Figure 1C ), ment (Cobleigh et al., 1999; Vogel et al., 2002) . Thus, there is an urgent need to identify patients who are unlikely to respond which paralleled a moderate increase of ErbB2 tyrosine phosphorylation by short-time trastuzumab treatment ( Figure 1A ). to trastuzumab treatment to spare them the potential side effects and unnecessary cost. More importantly, trastuzumab re-
The apparently paradoxical results indicate that, different from the previously reported mechanism of Akt dephosphorylation sistance-conferring factors may serve as molecular targets for overcoming trastuzumab resistance. Unfortunately, information that is dependent on ErbB2 downregulation or PI3K inhibition (Hudziak et al., 1989; Yakes et al., 2002) , the rapid Akt dephos-on the mechanisms of trastuzumab resistance in breast cancer cells is limited. Currently, there is no clinically verified factor phorylation by 1 hr trastuzumab treatment was not due to PI3K inhibition, nor by ErbB2 degradation and dephosphorylation, that can be used to predict trastuzumab resistance (Albanell and Baselga, 2001) .
but by some other novel mechanism. The tumor suppressor PTEN is a dual-phosphatase that PTEN (MMAC1/TEP) is a dual phosphatase that mainly dephosphorylates position D3 of membrane phosphatidylino-negatively regulates Akt activity (Cantley and Neel, 1999; Di Cristofano and Pandolfi, 2000; Leslie and Downes, 2002) . We sitol-3,4,5 trisphosphate (PI3,4,5P3), which is the site for recruiting the plecstrin-homology domain of Akt to the cell mem-thus asked whether PTEN activation may possibly be involved in the trastuzumab-mediated rapid Akt dephosphorylation before brane (Parsons and Simpson, 2003) . Since phosphatidylinositol 3-kinase (PI3K) catalyzes the production of PI3,4,5P3 (Cantley, PI3K inhibition and ErbB2 downregulation. We examined the PTEN phosphatase activity in untreated and trastuzumab-2002), PTEN antagonizes this PI3K function and negatively regulates Akt activities. Loss of PTEN function due to PTEN muta-treated (20 or 60 min) SKBr3 cells after immunoprecipitation (IP) of a similar amount of PTEN using the Ab-2 PTEN antibody tions, PTEN haploinsufficiency from LOH at the PTEN locus, and epigenetic downmodulation of PTEN have been reported ( Figure 1D , insert). Compared with untreated cells, 20 min trastuzumab treatment dramatically increased PTEN activity, which in nearly 50% of breast cancers and in many other cancer types (Li et al., 1997; Mutter et al., 2000; Parsons and Simpson, 2003;  continued to increase 60 min after treatment ( Figure 1D ). Similar results were obtained using another PTEN antibody (A2B1, not Teng et al., 1997; Whang et al., 1998) . Restoration of PTEN expression in PTEN null cells inhibits Akt activities and tumor shown). Therefore, trastuzumab treatment indeed led to a rapid increase of PTEN phosphatase activity that could account for formation (Li and Sun, 1998; Lu et al., 1999) . Therefore, PTEN is an important tumor suppressor gene. However, possible func-the rapid Akt dephosphorylation before ErbB2 is downregulated and before PI3K is inhibited. tional interactions of PTEN activity with ErbB2 receptor tyrosine kinase signaling and potential roles for PTEN in the antitumor Membrane-associated PTEN is known to be biologically active in cells (Comer and Parent, 2002; Iijima and Devreotes, activity of trastuzumab have never been explored. In this report, we demonstrate that PTEN activation is a novel mechanism 2002; Wu et al., 2000) . To investigate whether PTEN activation by trastuzumab is due to recruitment of PTEN to its biologically underlying trastuzumab's antitumor activity and that PTEN loss renders ErbB2-overexpressing breast cancer resistant to trastu-active subcellular location, we examined whether membrane localization of PTEN is increased by trastuzumab. After treating zumab-based therapy.
BT474 cells with or without trastuzumab for 20 min, we separated membrane bound proteins from cytosolic proteins in cell Results lysates and examined PTEN proteins by Western blotting ( Figure  1E ). In the untreated cells, the majority of PTEN protein was in Trastuzumab activates PTEN in breast cancer cells In our investigation of the mechanisms of trastuzumab's antitu-the cytosolic pool of the lysates, while a very low level of PTEN was detected in the membrane bound pool. This is consistent mor function, we observed that Ͼ20 hr trastuzumab treatment of BT474 and SKBr3 human breast cancer cell lines over-with the notion that PTEN is functionally inactivated in ErbB2overexpressing cancer cells (Cantley and Neel, 1999; Lu et al., expressing endogenous ErbB2 led to ErbB2 downregulation, dephosphorylation, and receptor internalization as expected 1999). However, upon trastuzumab treatment, PTEN protein in the membrane bound pool was noticeably enriched. Interest-(Lee et al., 2002) . However, 1 hr trastuzumab treatment (2-10 g/ml) did not induce ErbB2 downregulation, dephosphoryla-ingly, the MCF7 breast cancer cells with normal ErbB2 expression had more membrane bound PTEN than the ErbB2-overex-tion, and receptor internalization ( Figure 1A and Supplemental Figure S1 at http://www.cancercell.org.cgi/content/full/6/2/117/ pressing BT474 cells before trastuzumab treatment, yet a further increase of the membrane bound PTEN was not induced by DC1). Surprisingly, 1 hr trastuzumab treatment quickly reduced the level of phosphorylated and activated Akt in BT474 and trastuzumab in MCF7 cells (Supplemental Figure S2 ). These data suggest that in ErbB2-overexpressing breast cancer cells, SKBr3 cells while the Akt protein level remained unchanged ( Figure 1A ). It is known that Akt is constitutively activated in trastuzumab treatment specifically facilitates PTEN localization to the cell membrane, where this phosphatase is active and ErbB2-overexpressing cancer cells and Akt is inhibited after ErbB2 downregulation by trastuzumab, which is critical for tras-functions to dephosphorylate PIP 3 to PIP 2 , leading to Akt dephosphorylation. tuzumab's antitumor effect (Ignatoski et al., 2000; Yakes et al., 2002; Zhou et al., 2000) . However, the rapid Akt dephosphoryla-PTEN binds to the cellular membrane through its C2 domain and there are two tyrosine phosphorylation sites in the C2 do-tion by trastuzumab before ErbB2 downregulation has not been reported nor has its mechanisms. Since PI3K activation is the main of PTEN (Y240 and Y315) important for PTEN phosphatase activity and tumor inhibition function (Koul et al., 2002) . Tyrosine major upstream signaling event leading to Akt phosphorylation (Cantley, 2002) , we examined whether trastuzumab induced phosphorylation of PTEN reduces the capacity of the PTEN C2 domain to bind to the cellular membrane . Since rapid Akt dephosphorylation by inhibiting PI3K. However, PI3K activity was not inhibited within 1 hr of trastuzumab treatment we observed increased membrane localization of PTEN by tras- Figure 1 . Rapid Akt dephosphorylation and PTEN activation by trastuzumab A: Immunoblotting (IB) of ErbB2, Tyr1248-phosphorylated ErbB2 (p-ErbB2), phosphorylated Akt (p-Akt), and total Akt in trastuzumab (ϩ, 2 g/ml) or control IgG-treated (Ϫ, 2 g/ml) BT474 cells and SKBr3 cells. ␤-actin blot served as loading controls in all IB experiments. All in vitro experiments were repeated at least three times. Reproducible representative results are shown. B: PI3K assay after 2 g/ml of trastuzumab treatment of SKBr3 cells for the indicated time. Lysates were immunoprecipitated with the PY20 antibody followed by incubation in kinase buffer. Numbers below the panel indicate relative PI3K activity to untreated cells. IP with IgG served as a control. C: Trastuzumab transiently increased association of the p85 subunit of PI3K with the ErbB2 complex. ErbB2 immunoprecipitates and total cell lysates from untreated or trastuzumab-treated (2 g/ml) cells were immunoblotted with indicated antibodies. D: Increased PTEN phosphatase activities in trastuzumab-treated (2 g/ml) SKBr3 cells. Upper right insert shows, from left to right, immunoprecipitated PTEN proteins from untreated and trastuzumab-treated (20 or 60 min) cells. Immunoprecipitates by rabbit IgG from trastuzumabtreated cells were the negative control. E: Trastuzumab increased membrane bound PTEN in BT474 cells. PTEN protein in the cytosolic pool (sol) and the membrane bound pool (mem) of untreated (Ϫ) or trastuzumab-treated (ϩ, 2 g/ml) cell lysates were blotted with indicated antibodies. E-cadherin and ErbB2 were membrane protein markers. F: Reduction of PTEN tyrosine phosphorylation after trastuzumab treatment in BT474 cells. BT474 cells were treated without or with 2 g/ml of trastuzumab for the indicated time. PTEN IP using the A2B1 PTEN antibody was followed by IB with PY99 phosphotyrosine antibody (top). The membrane was then stripped and reprobed with A2B1 PTEN antibody to show the IP efficiency. IgG was used as a negative control. Numbers below the panel indicate relative levels of PTEN tyrosine phosphorylation with 0 min trastuzumab treatment defined as 1.
tuzumab treatment in ErbB2-overexpressing cells, we investi-PTEN is an early molecular event after trastuzumab treatment independent of ErbB2 downregulation and PI3K inhibition. gated whether this may result from reduced PTEN tyrosine phosphorylation. We immunoprecipitated PTEN from untreated or trastuzumab-treated BT474 cells with the A2B1 PTEN anti-Trastuzumab activates PTEN by inhibiting Src body and immunoblotted with the PY99 phosphotyrosine antiassociation with ErbB2 body ( Figure 1F ). Consistent with the notion that PTEN is func-To investigate how trastuzumab inhibits PTEN tyrosine phostionally inactive in ErbB2-overexpressing cells (Lu et al., 1999) , phorylation, we examined whether trastuzumab may inhibit Src tyrosine kinase, since Src activation has recently been reported we found that PTEN is highly phosphorylated on tyrosine in untreated BT474 cells. However, trastuzumab treatment rapidly to increase PTEN tyrosine phosphorylation . Compared to untreated cells, trastuzumab treatment rapidly reduced PTEN tyrosine phosphorylation in BT474 cells ( Figure  1F ), which paralleled the increased PTEN membrane localization inhibited Src kinase activity ( Figure 2A ) and rapidly reduced Src phosphorylation on Y416 ( Figure 2B ), an indicator of Src activity and PTEN activation by trastuzumab in these cells (Figures 1D and 1E) . Thus, trastuzumab induces PTEN activation by (Frame, 2002) . Reduced Src-Y416 phosphorylation corresponded to reduced PTEN tyrosine phosphorylation ( Figure 2B ). increasing the translocation of PTEN from the cytoplasm to the membrane through reducing the inhibitory tyrosine phosphory-Src is known to bind to ErbB2 and is thus activated in ErbB2overexpressing cancer cells (Belsches-Jablonski et al., 2001; lation of PTEN. Notably, these events occur before ErbB2 is downregulated and PI3K is inhibited. Therefore, activation of Muthuswamy and Muller, 1995). To explore the mechanisms of A: Trastuzumab treatment inhibits Src kinase activity. BT474 cells were either untreated (N/T) or treated with 2 g/ml trastuzumab (Ttzm) for the indicated time. Src kinase activity was assayed as in Experimental Procedures. B: Trastuzumab treatment inhibits Src-Y416 phosphorylation. BT474 cells were treated similarly as in Figure 1E . Cytosolic pool (sol) and membrane bound pool (mem) lysates were blotted with the indicated antibodies. C: Trastuzumab induces Src dissociation from ErbB2. BT474 cells were treated with trastuzumab for the indicated time. trastuzumab-mediated Src inhibition, we examined whether Src the PTEN membrane translocation in the 435.eB cells, PTEN membrane translocation by trastuzumab in the eB/SrcCA cells binding to ErbB2 is inhibited by trastuzumab treatment in BT474 cells. Trastuzumab induced a very rapid and dramatic reduction expressing constitutively activated Src was less effective ( Figure  2G ). Together, our data indicate that trastuzumab treatment of ErbB2 bound Src ( Figure 2C ), indicating that trastuzumab inhibited Src activity in ErbB2-overexpressing cells most likely inhibits Src binding to ErbB2 in ErbB2-overexpressing breast cancer cells, thus inhibiting Src kinase activity, which leads to by inhibiting Src binding to ErbB2.
To further confirm that Src inhibition can reduce PTEN tyro-reduced PTEN tyrosine phosphorylation and increased PTEN membrane localization and activity. sine phosphorylation in ErbB2-overexpressing breast cancer cells, we examined whether the Src kinase inhibitor PP2 may reduce PTEN tyrosine phosphorylation in the ErbB2-overex-PTEN activation contributes to trastuzumab's antiproliferation function pressing 435.eB breast cancer cells (Yu et al., 1998a) . Compared to the solvent 10% dimethyl sulfoxide (DMSO)-treated Trastuzumab is known to inhibit the growth of ErbB2-overexpressing breast cancer cells through the downregulation of 435.eB cells, PP2 treatment effectively inhibited Src phosphorylation on Y416 ( Figure 2D ) and also dramatically reduced tyro-ErbB2 and the subsequent inhibition of its downstream PI3K-Akt signaling pathway (Hudziak et al., 1989; Yakes et al., 2002) . sine phosphorylation of PTEN, similar to trastuzumab's effect ( Figure 2E ). Contrarily, the eB/SrcCA cells, which are 435.eB
Since we found that trastuzumab activates PTEN before ErbB2 is downregulated and before PI3K is inhibited, it is imperative cells stably expressing a constitutively activated Src (Chan et al., 2003) and having higher levels of Src-Y416 phosphorylation to determine whether PTEN activation indeed caused the rapid Akt dephosphorylation and contributes to the antiproliferation and Src activity, showed a dramatic increase of PTEN tyrosine phosphorylation compared to the 435.eB cells ( Figure 2F ). Fur-function of trastuzumab. To achieve this, we transfected SKBr3 breast cancer cells with PTEN antisense (AS) oligonucleotides thermore, although trastuzumab treatment effectively increased were treated with trastuzumab (2 g/ml) for the indicated times, and cell lysates were immunoblotted. C: Trastuzumab inhibited cell proliferation less in PTEN AS-treated SKBr3 cells compared to MIStransfected cells. MIS or PTEN AS-transfected SKBr3 cells (as in A) were treated with trastuzumab (2 g/ml) for 3 and 5 days. Cell mass was determined by MTS assay. Percent cell number represents % cell counts under each treatment relative to untreated cells. D: Similar cell growth in MIS-or PTEN AS-transfected SKBr3 cells without trastuzumab. Percent cell numbers represents % cell counts compared to Day 1 (defined as 100%). E: PTEN-reduced BT474 cells are more resistant to trastuzumab plus paclitaxel than PTEN normal cells but have a similar paclitaxel response to PTEN normal cells. BT474 cells were transfected with 25 nM MIS or PTEN AS, treated by paclitaxel (1, 2, and 4 nM) without or with 2 g/ml of trastuzumab (Ttzm) for 3 days. Percent cell viability are cell mass as a % of untreated MIS-transfected cells. F: PTEN expression is reduced in BT474 xenografts injected with PTEN AS. BT474 cells were inoculated into the mfp of female nude mice. After tumors reached 150 mm 3 , MIS or PTEN AS were injected intratumor (15 g/injection, twice a week) for 1 week. Removed tumors were stained with antibodies to PTEN and ErbB2. G: PTEN-deficient BT474 xenografts are more resistant to trastuzumab than PTEN normal BT474 xenografts. After 1 week of PTEN AS or MIS treatment (as in F), mice were treated with trastuzumab (10 mg/kg) or vehicle twice a week. The arrows indicate the starting days of AS/MIS treatment (AS) and trastuzumab/vehicle treatment (Ttzm). The results shown are the mean tumor volume ϩ SE; *p Ͻ 0.05. (Butler et al., 2002) , which effectively reduced endogenous ( Figure 3C ). We observed similar results in BT474 cells (Supplemental Figure S3 ). These data demonstrate that normal PTEN PTEN expression compared to mock-transfected cells or cells transfected with control mismatched (MIS) oligonucleotides levels are required for the antiproliferation function of trastuzumab. Without trastuzumab treatment, PTEN reduction by PTEN ( Figure 3A) . Compared with MIS control-treated cells showing rapid Akt dephosphorylation by trastuzumab ( Figure 3B, top) , AS alone had no significant effect on cell proliferation ( Figure  3D) , which was consistent with the similar Akt phosphorylation Akt dephosphorylation was attenuated in PTEN AS-treated cells (Figure 3B, bottom) . This indicates that PTEN is required for the levels in cells treated with PTEN AS alone to that treated with MIS control (Figure 3B, time 0) . That blocking PTEN only re-rapid Akt dephosphorylation by trastuzumab. To investigate whether PTEN activation contributes to trastuzumab's antiprolif-duced trastuzumab's antiproliferative function but had no effect on cells without trastuzumab treatment reiterated that PTEN eration function, we compared cell growth between MIS control and PTEN AS-transfected SKBr3 cells after trastuzumab treat-activity is important for trastuzumab function, which reconciles well with our finding that PTEN is activated by trastuzumab ment. PTEN AS-treated cells with reduced PTEN showed significantly less growth inhibition by trastuzumab than MIS con-( Figures 1D-1F ). Thus, PTEN reduction led to resistance to the antiproliferation effect of trastuzumab in these cells.
trol-transfected SKBr3 cells having normal PTEN expression
Trastuzumab is mostly used in combination with other chemotherapeutics in the clinic (Slamon et al., 2001) . Therefore, we further examined whether PTEN reduction may confer breast cancer cell resistance to trastuzumab plus paclitaxel chemotherapy. We transfected BT474 cells with PTEN AS or MIS control oligonucleotides, then treated them with or without trastuzumab (2 g/ml) plus different concentrations of paclitaxel (1, 2, and 4 nM) and measured cell viability 3 days later. MIS controltreated cells with normal PTEN expression showed significant growth inhibition by trastuzumab plus paclitaxel (p Ͻ 0.05), whereas PTEN AS-transfected cells were not inhibited ( Figure  3E, top) . However, paclitaxel alone without trastuzumab showed no statistically significant difference in cell viability between PTEN AS-and MIS control-transfected cells ( Figure 3E, bottom) , indicating that PTEN status does not significantly impact breast cancer cell sensitivity to paclitaxel but specifically impacts trastuzumab sensitivity. These results indicate that breast cancer cells with reduced PTEN are resistant to growth inhibition by trastuzumab as a single agent ( Figure 3C ) as well as in combination with paclitaxel ( Figure 3E ).
PTEN deficiency contributes to trastuzumab resistance in vivo
To investigate if PTEN deficiency may confer breast cancer cell resistance to trastuzumab in vivo, we injected a tumorigenic subline of BT474 cells into the mammary fat pad (mfp) of athymic nude mice. When tumor xenografts reached Ͼ150 mm 3 , we injected PTEN AS or MIS oligonucleotides into the tumor xenografts. One week later, we treated mice with trastuzumab (10 mg/kg) or vehicle twice per week. PTEN expression in tumor xenografts was effectively inhibited by PTEN AS when ErbB2 expression remained the same ( Figure 3F ). Trastuzumab only inhibited MIS control-treated tumors expressing normal PTEN, but not PTEN AS-treated tumors with reduced PTEN ( Figure  3G ). Without trastuzumab treatment, PTEN AS-and MIS-treated tumors had similar tumor growth rates ( Figure 3G ). These results demonstrated that PTEN reduction confers breast tumor xeno- The above data clearly demonstrate that PTEN deficiency con-**p Ͻ 0.01. fers trastuzumab resistance in breast cancer. In search of strate-B: BT474 cells were treated with MIS or PTEN AS as in Figure 3A . Cells were then treated with trastuzumab (2 g/ml), Wortmannin (WN, 1 M), or tras-gies for overcoming trastuzumab resistance from the loss of tuzumab plus Wortmannin (Ttzm ϩ WN) for 3 days. Percent inhibition is PTEN, we reasoned that since PI3K antagonizes PTEN function, % growth reduction under each treatment relative to untreated cells.
inactivation of PI3K may rescue trastuzumab resistance from **p Ͻ 0.01. PTEN deficiency. We investigated whether PI3K inhibitors that C: BT474 xenografts were treated with PTEN AS as in Figure 3G . Mice were are known to quickly induce Akt dephosphorylation in ErbB2treated with trastuzumab (10 mg/kg) twice a week or/and LY294002 (100 mg/kg) 3 times a week for 3 weeks. The arrows indicate the starting days overexpressing cells may reverse trastuzumab resistance in of AS treatment (AS) and trastuzumab and/or LY294002 treatment (Ttzm, PTEN-deficient breast cancer cells (Xiong et al., 2001) . We trans-LY). The results are the mean tumor volume ϩ SE. *p Ͻ 0.05. fected BT474 cells with MIS and PTEN AS oligonucleotides, then treated them with trastuzumab, the PI3K inhibitor LY294002, or trastuzumab plus LY294002. We then determined cell viability 3 days later ( Figure 4A ). The MIS-treated cells are more sensitive mannin, in combination with trastuzumab, also inhibited PTEN to trastuzumab-mediated growth inhibition than the PTEN AS-AS-treated BT474 cells significantly better than either treatment treated cells, and the combination treatment inhibited the viabilalone (p Ͻ 0.01), whereas the combination had a similar inhibiity of MIS-treated cells slightly better than trastuzumab alone tory effect as trastuzumab alone in MIS-treated cells ( Figure 4B ). or LY294002 alone (p Ͼ 0.05). However, the LY294002 plus In vivo, trastuzumab combined with the PI3K inhibitor LY294002 trastuzumab combination inhibited cell viability significantly betwas also significantly (p Ͻ 0.05) more effective than trastuzumab ter than trastuzumab alone or LY294002 alone in PTEN ASalone or LY294002 alone in inhibiting PTEN AS-treated BT474 tumor xenografts in mice ( Figure 4C ). These results indicate treated cells (p Ͻ 0.01). Similarly, another PI3K inhibitor, Wort-that PI3K inhibitors could overcome trastuzumab resistance in PTEN-deficient breast cancer cells.
Patients with PTEN-deficient breast cancers have a poor clinical response to trastuzumab
To explore the clinical significance of PTEN status in predicting response to trastuzumab-based therapy in patients, we evaluated PTEN expression in 47 ErbB2-overexpressing primary breast carcinomas from patients who subsequently developed metastatic breast cancer and received trastuzumab plus taxane (paclitaxel or docetaxel) therapy (Esteva et al., 2002; Seidman et al., 2001) . As controls, we evaluated PTEN expression in primary breast carcinomas not selected for ErbB2 overexpression from 37 patients who subsequently developed metastatic breast cancer and received taxane without trastuzumab (Holmes et al., 1991; Valero et al., 1995) . Immunohistochemical staining using PTEN antibodies revealed that PTEN expression in these tumors was heterogeneous with different intensities. Thus, PTEN expression levels were semiquantified using immunoreactive scores (IRS) calculated by multiplying the percentage of PTEN-positive cells (scored 0 to 4) with the PTEN staining intensity (1 to 3) (Chui et al., 1996) . IRS of 0 to 12 represents PTEN staining from a nondetectable level in PTEN-lost tumors to full expressions in normal individuals ( Figure 5A ). We observed PTEN loss (IRS Ͻ 9) in 36.2%-43.2% of the tumors examined (17/47 and 16/37), which is consistent with previous reports on loss of PTEN expression in ‫%04ف‬ breast cancers using immunohistochemistry (IHC) staining (Depowski et al., 2001; Perren et al., 1999) . Remarkably, among the 47 breast cancer patients who received trastuzumab plus taxane, patients with PTEN-deficient tumors (IRS 0-6) had significantly lower complete and partial response (CRϩPR) rates to trastuzumab plus taxane therapy than patients with PTEN-positive tumors (35.7% versus 66.7%, p Ͻ 0.05) ( Figure 5B, left) . Using more stringent criteria for PTEN loss (IRS Ͻ 4), patients with PTEN-negative tumors demonstrated a striking, highly significant (p Ͻ 0.01) Figure 5B, right) . Furthermore, we identified a statistically sig- (IHC 3ϩ, 2ϩ, primary breast carcinomas were colnificant trend suggesting that the probability of response to lected from 47 patients who subsequently received trastuzumab plus taxane (paclitaxel or docetaxel) on IRB-approved clinical trials conducted at trastuzumab decreases as PTEN IRS decreases (p Ͻ 0.01) (Supthe UT M.D. Anderson Cancer Center (Esteva et al., 2002; Seidman et al., plemental Figure S4 ). However, among the 37 patients treated 2001). PTEN expression in these tumors was examined by IHC and semiquanby taxane without trastuzumab, patients with PTEN-deficient Figure S5 ). These data clearly demonstrate that **p Ͻ 0.01. Complete response (CR), partial response (PR), stable disease PTEN loss does not confer breast cancer resistance to taxane (SD), and progressive disease (PD). n, number of patients studied.
but specifically to trastuzumab. To confirm that PTEN is a spe-C: Trastuzumab plus taxane response rates in patients with ErbB2 FISH-positive and/or IHC 3ϩ breast cancers versus patients with ErbB2 FISH-negative cific marker for trastuzumab response, we examined whether and/or IHC 2ϩ cancers (p Ͼ 0.05). clinical responses to trastuzumab plus taxane treatment (Supplemental Figure S6 ). It has been reported that patients with ErbB2 FISH-positive and/or IHC 3ϩ breast cancers respond to trastuzumab better than patients with ErbB2 FISH-negative significant ( Figure 5C ). However, among patients with ErbB2 and/or 2ϩ cancers (Vogel et al., 2002) . Although we see a similar FISH-positive and/or IHC 3ϩ breast cancers, patients with tendency (59% for FISH-positive and/or IHC 3ϩ versus 37% PTEN-deficient tumors (IRS 0-3) had significantly lower refor FISH-negative and/or IHC 2ϩ) among the 47 patients treated with trastuzumab plus taxane, the difference was not statistically sponse (CRϩPR) rates than patients with PTEN-positive tumors (12.5% versus 71%, p Ͻ 0.01) ( Figure 5D ). The data indicate normal PTEN, and the difference was statistically highly signifithat PTEN status is a unique and powerful marker for predicting cant (p Ͻ 0.01) even in this small cohort. Thus, the PTEN status clinical response to trastuzumab-based therapy.
of ErbB2-overexpressing breast tumors may be used as a predictive factor for patients' trastuzumab response in the clinic.
Discussion
PTEN loss in an ErbB2-overexpressing breast tumor can also serve as an indication that the patient needs combination ther-Trastuzumab has been a model of a rationally designed, highly apy with PI3K inhibitors to overcome the PTEN loss-mediated specific, targeted cancer therapy and has brought valuable thertrastuzumab resistance to receive the maximum therapeutic apeutic benefits to patients with ErbB2-overexpressing cancers benefit of trastuzumab. Large-scale clinical investigations will (Albanell and Baselga, 2001; Dickman, 1998) . However, the limbe performed to further validate these ideas. ited response rates of trastuzumab, even in patients with tumors Loss of PTEN function from PTEN mutations was reported expressing very high levels of ErbB2, raises questions on the in 5%-10% of human breast cancers, and PTEN haploinsuffimechanisms of trastuzumab function (other than those related ciency due to loss of heterozygosity at the PTEN locus can be to the inhibition of ErbB2 signaling) and on the mechanisms of found in nearly 50% of breast tumors (Li et al., 1997 ; Teng et trastuzumab resistance in patients. Here, we report that the al., 1997). In addition, epigenetic downmodulation of PTEN has phosphatase function of the tumor suppressor PTEN is rapidly also been reported (Mutter et al., 2000; Whang et al., 1998) . activated by trastuzumab before it downregulates the ErbB2
Consistent with these reports, we identified PTEN deficiencies receptor. This finding led to the new concept that PTEN activain ‫%04ف‬ of breast cancers in our two small cohorts, indicating tion is a novel mechanism that contributes to trastuzumab's that the PTEN loss rate is similar among patients with ErbB2antitumor activity independent of its well-known function of overexpressing tumors and breast cancer patients in general. ErbB2 downregulation. We also found that trastuzumab acti-Our finding that PTEN deficiency confers trastuzumab resisvated PTEN by inhibiting PTEN tyrosine phosphorylation tance in ErbB2-overexpressing breast cancers could directly through reducing the ErbB2 receptor bound Src-thus inhibiting impact the clinical management of these patients with Src, a tyrosine kinase for PTEN . This indicates PTEN-deficient tumors. In light of this, we have shown that PI3K a functional crosstalk between the ErbB2 receptor and the PTEN inhibitors could overcome PTEN loss-induced trastuzumab retumor suppressor in breast cancer cells via Src: Src plays imporsistance in ErbB2-overexpressing breast cancer cells in vitro tant oncogenic functions (e.g., inactivates PTEN) when bound and in vivo. This suggests that members of the PI3K pathway, as to and activated by overexpressed ErbB2, whereas trastuzumab well as PTEN, are molecular targets for overcoming trastuzumab dissociates Src from ErbB2, inhibits Src, and thus activates resistance. These new insights will guide the future development PTEN, which contributes to the trastuzumab antitumor function.
of agents for overcoming trastuzumab resistance and novel This newly identified mechanism of trastuzumab function targeted cancer therapies to benefit cancer patients. clearly indicates that trastuzumab responsiveness depends not only on the downregulation of ErbB2 and the inhibition of ErbB2-Experimental procedures related downstream events, but also on the status of PTEN.
Antibodies and reagents
Indeed, our data from cultured breast cancer cell lines, mouse PTEN antibodies were from Santa Cruz Biotechnology (A2B1, Santa Cruz, tumor xenografts, and most importantly, from clinical samples CA) and Lab Vision Corp. (Ab2, Fremont, CA); antibodies to Akt, phosphoof breast cancer patients consistently demonstrated that PTEN Akt, and Y416-phosphorylated Src were from Cell Signaling Technology deficiency is a molecular mechanism that confers ErbB2-over- (Beverly, MA) ; antibodies to ErbB2 and v-Src (Ab-1) were from Calbiochem expressing breast cancers resistance to trastuzumab-based (La Jolla, CA); antibodies to the 85 kDa subunit of PI3K, phospho-ErbB2, therapy and that PTEN loss was associated with trastuzumab and phospho-tyrosine (4G10) were from Upstate Biotechnology, Inc. (Waltham, MA); antibody to phosphotyrosine (PY20) was from BD Biosciences resistance in patients. The response rate of trastuzumab as a (San Diego, CA); and trastuzumab was from Genentech, Inc. (San Francisco, single agent was reported higher in patients with ErbB2 FISH-CA). LY294002 was from Cell Signaling Technology; Wortmannin, PP2, and positive and/or IHC 3ϩ breast cancers than in patients with AG1879 were from Calbiochem; Enolase was from was Sigma (St. Louis, ErbB2 FISH-negative and/or 2ϩ tumors (Vogel et al., 2002) . We MO); and taxol was from Bristol Myers-Squibb (Princeton, NJ). Src/CA muobserved a similar, but not significant, trend in our small cohort (Li et al., 1997). than those with PTEN-positive tumors (p ϭ 0.004). Thus, the PTEN status seems to be a more sensitive and specific predictor PI3K activity assay PI3K activities were determined in the PY20 antibody immunoprecipitates for trastuzumab-based therapy. of untreated or trastuzumab-treated lysates as we did previously (Tan et al., Insulin-like growth factor-I receptor (IGF-IR) signaling was 1999). implicated in trastuzumab resistance, but it has not been validated with clinical data (Lu et al., 2001) . Remarkably, our finding Src kinase assay that PTEN deficiency confers trastuzumab resistance is strongly Equal amounts of cell lysates were immunoprecipitated with anti-Src antisupported by clinical data that patients with PTEN-deficient body (OP07, Oncogene Research Products, Boston, MA). The precipitates were washed and incubated with 250 g/ml enolase, 2 Ci of [␥-32 P]ATP, tumors did not respond to trastuzumab as well as those with and 3 l of 100 mM ATP in 40 l of kinase buffer. After 30 min at 37ЊC, the in saline was delivered by multiple intratumor injection as described (Urano et al., 2002) . A week later, mice received trastuzumab (10 mg/kg) or vehicle samples were boiled in 15 l of 6ϫSDS sample buffer for 5 min and then subjected to SDS-PAGE. The 32 P-labeled enolase was visualized by autoradi-(PBS) twice/week, combined with LY294002 (100 mg/kg) or vehicle (DMSO) three times/week. Tumor diameters were serially measured with calipers ography. and tumor volumes calculated: volume ϭ width 2 ϫ length/2. Each treatment group had 8-12 mice. Unpaired Student's t test was used to assess statistical Antisense delivery in vitro significance. Antisense (AS) oligonucleotides against PTEN (ISIS 116847: 5Ј-CTGCTAGC CTCTGGATTTGA-3Ј) and control oligonucleotides (ISIS 116848: 5Ј-CTTCTG Patient samples GCATCCGGTTTAGA-3Ј) have been described (Butler et al., 2002) . Cells ErbB2-overexpressing primary breast carcinomas were collected from 47 were plated in 100 mm dishes at 30% confluence and transfected with patients who subsequently developed metastatic breast cancer and received oligonucleotides (12.5 nM for BT474 and 25 nM for SKBr3 cells) twice using trastuzumab plus taxane (paclitaxel or docetaxel) (Esteva et al., 2002 ; Seid-Oligofectamine (Life Technologies, Rockville, MD) 24 and 72 hr postplating. man et al., 2001) . Primary breast carcinomas not selected for ErbB2-overex-Cells were replated for individual assays described in this report 96 hr pressing tumors from 37 patients who subsequently developed metastatic postplating. PTEN expression was determined 120 hr postplating ( Figure 3A) . breast cancer and received taxane without trastuzumab were collected as controls (Holmes et al., 1991; Valero et al., 1995) . The 47 patients were Cell viability assay treated between 1998 and 2001 and the 37 patients were treated between 1-5 ϫ 10 3 cells/well were seeded in 96-well plates after transfection. Viable 1990 and 1991 under IRB-approved clinical trials at The University of Texas cells were determined by CellTiter 96 AQueous Non-Radioactive Cell Prolifer-M.D. Anderson Cancer Center. Association between clinical response to ation Assay (Promega, Madison, WI).
therapy and PTEN status was tested using chi-square and Fisher's tests. Cell lysates preparation, IP, and IB PTEN IHC and evaluation Cells at 70%-80% confluence were treated with each reagent indicated in Slides (4 m) of formalin-fixed, paraffin-embedded tissue sections were the individual experiments. For PTEN phosphotyrosine immunoblots, ErbB2 incubated with PTEN antibody (Ab-2, 1:500) as described (Podsypanina et IP, and Src IP, cells were treated with 30 M pervanadate for 10 min as al., 2001). IHC was performed with LSAB2 kit (DAKO, Carpinteria, CA), described . Cells were washed with PBS and lysed in IP color development with 3-3Ј-diaminobenzidine, and counterstaining with buffer with protease inhibitor cocktail (Sigma). IP and IB were performed as hematoxylin. PTEN expression level was scored semiquantitatively based described (Yu et al., 1998b) .
on staining intensity and distribution using the immunoreactive score (IRS) as described (Chui et al., 1996; Friedrichs et al., 1993) and as following: PTEN phosphatase assay IRS ϭ SI (staining intensity) ϫ PP (percentage of positive cells). SI was PTEN phosphatase activity was measured as described with minor modidetermined as 0 ϭ negative; 1 ϭ weak; 2 ϭ moderate; and 3 ϭ strong. PP fications (Georgescu et al., 1999) . Lysates were precleared with protein was defined as 0, Ͻ1%; 1, 1%-10%; 2, 11%-50%; 3, 51%-80%; and G-agarose beads to eliminate trastuzumab used as treatments prior to IP 4, Ͼ80% positive cells. Ten visual fields from different areas of each tumor with PTEN antibodies (Ab-2 or A2B1). After IP, the beads were washed once were used for the IRS evaluation. Negative control slides without primary in lysis buffer; five times in low-stringency buffer containing 20 mM HEPES antibody were included for each staining. Normal breast epithelium or vascu-(pH 7.7), 50 mM NaCl, 0.1 mM EDTA, and 2.5 mM MgCl 2 ; and once in lar endothelium known to express normal PTEN was used as positive conphosphatase assay buffer lacking PIP 3 . Assays were performed for 40 min trols. at 37ЊC in 50 l buffer containing 100 mM Tris-HCl (pH 8.0), 10 mM DTT, and 100 M water-soluble diC8-PIP 3 substrate (Echelon, Salt Lake City, UT)
ErbB2 status in a 96-well plate. Release of phosphate from substrate was measured ErbB2 gene amplification in patients' samples was assayed by fluorescence using Biomol Green Reagent (Biomol Research Laboratories, Inc., Plymouth in situ hybridization (FISH) using PathVysion FISH assay (Vysis, Inc., IL). Meeting, PA).
ErbB2 protein was determined by IHC as described (Jacobs et al., 1999) .
Separation of membrane bound and cytosolic proteins

